
Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer
Personalis Expands Tempus Partnership to Deliver Ultra-Sensitive Recurrence Testing for Colorectal Cancer Today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization…












